OBJECTIVES: To assess the influence  and role of antineoplastic and immunomodulating agents in works and recommendations of AOTM. The main role of AOTM, established  in  2005, is to assess, appraise and prepare recommendations on financing all medical technologies and services claiming public money founding. Full pharmacoeconomic evaluations of new therapies are required for all reimbursement  decisions. Manufacturers of antineoplastic and immunomodulating drugs are obligated to provide HTA reports in order to have their drug reimbursed.  Recommendations issued by AOTM have been based on Manufacturer`s submission, additional published data, experts and Polish public payer opinions. METHODS: All recommendations issued by the AOTM until the end of 2011 were reviewed and analyzed from the official website of AOTM. The recommendations related to antineoplastic and immunomodulating drugs were distinguished. RESULTS: Among 400 AOTM recommendations analyzed, the largest number, 142 of 400 (36%) was connected with antineoplastic and immunomodulating agents. 105 (74%) of them regarding oncology treatment. Recommendation for non–drug technologies were issued to 47 (12%) of 400 technologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34 (9%)  metabolic disorders, 31 (8%) were related to cardiovascular drugs,  21 (5%)  genito-urinary system. 15% of verified documentations applied to other, single  indications. CONCLUSIONS: The number of recommendations issued  for antineoplastic and immunomodulating drugs in comparison to other medicines reflects the importance and significance of this area of medicine. Documents prepared by AOTM related to antineoplastic (cancer chemotherapy) treatment represent standards and trends in contemporary medicine.